Drug Search Results
More Filters [+]

Eptotermin alfa

Alternative Names: eptotermin alfa, bmp-7, bmp 7, bmp7
Latest Update: 2023-09-26
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: TGFR Inhibitor

Novel Mechanism: No

Modality: Large Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Austria | European Medicines Agency | Germany | Hungary | Ireland | Italy | Lithuania | Portugal | Spain | Sweden | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Stryker
Company Location: KALAMAZOO MI 49002
Company CEO: Kevin A. Lobo
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Eptotermin alfa

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Tibial Fractures|Other

Phase 3: Pain Unspecified

Phase 2: Cleft Lip|Cleft Palate|Femoral Fractures|Femoral Neck Fractures

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

BMP7

N/A

Terminated

Femur Head Necrosis

2017-05-01

2006-006727-39

P4

Completed

Unknown

2015-10-18

NCT00551941

P4

Terminated

Tibial Fractures

2012-07-09

The use of BMP for alveolar reconstruction

P2

Terminated

Cleft Lip|Cleft Palate

2010-11-01

Recent News Events